Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORY-2001 open-label phase 2 study in aggression associated with neuropsychiatric and neurodegenerative disorders
2018-002140-88Phase 2Completed
- Sponsor
- Oryzon Genomics
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vafidemstat in Aggression (not a disease; see rationale), sponsored by Oryzon Genomics. Primary endpoint: Safety. Started Jul 2018; status: completed.
02
Drugs
vafidemstat
03
Conditions
Aggression (not a disease; see rationale)
Beyond the preview
Go deeper on 2018-002140-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002140-88.